지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2014.1
- 수록면
- 287 - 292 (6page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Only moderate to severe Crohn’s Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria. Methods: A retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn’s Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline. Results: A total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy. Conclusions: Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Sung JJ / 2010 / Asian perspectives in the management of inflammatory bowel disease : findings from a recent survey / J Gastroenterol Hepatol 25:183~193
Rieder F / 2008 / Intestinal fibrosis in inflammatory bowel disease-current knowledge and future perspectives / J Crohns Colitis 2:279~290
Tursi A / 2014 / Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn’s disease patients in primary gastroenterology centres / Eur J Intern Med 25:485~490
Rutgeerts P / 2012 / Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease : data from the EXTEND trial / Gastroenterology 142:1102~1111
Peters CP / 2014 / Adalimumab for Crohn’s disease : long-term sustained benefit in a population-based cohort of 438 patients / J Crohns Colitis 8:866~875
Rieder F / 2008 / Intestinal fibrosis in inflammatory bowel disease-current knowledge and future perspectives / J Crohns Colitis 2:279~290
Tursi A / 2014 / Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn’s disease patients in primary gastroenterology centres / Eur J Intern Med 25:485~490
Rutgeerts P / 2012 / Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease : data from the EXTEND trial / Gastroenterology 142:1102~1111
Peters CP / 2014 / Adalimumab for Crohn’s disease : long-term sustained benefit in a population-based cohort of 438 patients / J Crohns Colitis 8:866~875
이 논문의 저자 정보
최근 본 자료
댓글(0)
0